Orkin Wins Breakthrough Prize in Life Sciences

Pioneering research on fetal hemoglobin regulation leads to new sickle cell disease treatment

Apr. 20, 2026 at 9:26am

Got story updates? Submit your updates here. ›

A highly structured abstract painting in muted earth tones, featuring sweeping geometric arcs, concentric cellular structures, and precise biological spirals, visualizing the complex mechanisms of hemoglobin regulation that were the focus of Orkin's pioneering work.A conceptual illustration of the groundbreaking research that led to a new gene-editing therapy for sickle cell disease, transforming the lives of patients.Los Angeles Today

Stuart H. Orkin, MD, Investigator at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, has been awarded the prestigious Breakthrough Prize in Life Sciences for his groundbreaking discovery of how the body turns off fetal hemoglobin after birth. This finding paved the way for a new gene-editing therapy that reactivates fetal hemoglobin, dramatically improving outcomes for sickle cell disease patients.

Why it matters

Orkin's work on the molecular mechanisms controlling the switch from fetal to adult hemoglobin production represented a major breakthrough in hematology. His discovery of the BCL11A regulator provided a new therapeutic target, leading to the development of a transformative gene-editing treatment for sickle cell disease, a debilitating condition that disproportionately affects minority populations.

The details

In a landmark 2008 study, Orkin's team identified BCL11A as a key "off switch" for fetal hemoglobin production. This discovery offered a new approach: reducing BCL11A activity could restore fetal hemoglobin levels and compensate for the defective adult hemoglobin that drives sickle cell disease. Subsequent research in animal models validated this strategy, paving the way for gene-editing therapies that target BCL11A regulation in a patient's own blood stem cells.

  • Orkin's seminal paper on BCL11A was published in the journal Science in 2008.
  • Clinical studies of gene-edited therapies based on Orkin's work have shown striking results in recent years, dramatically reducing or eliminating painful sickle cell crises.

The players

Stuart H. Orkin, MD

Investigator at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, David G. Nathan Distinguished Professor at Harvard Medical School, and Investigator at Howard Hughes Medical Institute. His pioneering research on fetal hemoglobin regulation led to a new treatment strategy for sickle cell disease.

SweeLay Thein

Investigator at the National Institutes of Health (NIH), who shared the Breakthrough Prize in Life Sciences with Orkin for their collaborative work on sickle cell disease.

Got photos? Submit your photos here. ›

What they’re saying

“For us, the long arc of discovery has really come full circle. I started at a time when we could not clone genes, and now we can treat patients through gene modification and see them well.”

— Stuart H. Orkin, Investigator, Dana-Farber/Boston Children's Cancer and Blood Disorders Center

“For the sickle cell patients, they no longer have crises, pain crises. After therapy, they're now having a totally new future. And so, it really is transformative.”

— Stuart H. Orkin, Investigator, Dana-Farber/Boston Children's Cancer and Blood Disorders Center

What’s next

Orkin and his team will continue to refine and expand the gene-editing therapies based on their discoveries, with the goal of making this treatment widely available to sickle cell disease patients around the world.

The takeaway

Orkin's pioneering work on fetal hemoglobin regulation represents a remarkable scientific breakthrough with profound implications for improving the lives of sickle cell disease patients. His discovery has paved the way for a transformative gene-editing therapy, demonstrating the power of fundamental research to drive life-changing medical innovations.